- Home
- MGIH vs SYBX Comparison
MGIH vs SYBX Comparison
Compare MGIH & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIH
- SYBX
- Stock Information
- Founded
- MGIH 1978
- SYBX N/A
- Country
- MGIH Hong Kong
- SYBX United States
- Employees
- MGIH N/A
- SYBX N/A
- Industry
- MGIH Publishing
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- MGIH Consumer Discretionary
- SYBX Health Care
- Exchange
- MGIH Nasdaq
- SYBX Nasdaq
- Market Cap
- MGIH 20.1M
- SYBX 16.5M
- IPO Year
- MGIH 2023
- SYBX N/A
- Fundamental
- Price
- MGIH $1.82
- SYBX $1.46
- Analyst Decision
- MGIH
- SYBX Hold
- Analyst Count
- MGIH 0
- SYBX 3
- Target Price
- MGIH N/A
- SYBX $1.00
- AVG Volume (30 Days)
- MGIH 5.0M
- SYBX 25.8K
- Earning Date
- MGIH 10-30-2024
- SYBX 11-12-2024
- Dividend Yield
- MGIH N/A
- SYBX N/A
- EPS Growth
- MGIH N/A
- SYBX N/A
- EPS
- MGIH N/A
- SYBX N/A
- Revenue
- MGIH $38,530,773.00
- SYBX $2,777,000.00
- Revenue This Year
- MGIH N/A
- SYBX N/A
- Revenue Next Year
- MGIH N/A
- SYBX N/A
- P/E Ratio
- MGIH N/A
- SYBX N/A
- Revenue Growth
- MGIH N/A
- SYBX 292.23
- 52 Week Low
- MGIH $0.98
- SYBX $1.22
- 52 Week High
- MGIH $9.57
- SYBX $3.73
- Technical
- Relative Strength Index (RSI)
- MGIH 51.48
- SYBX 53.64
- Support Level
- MGIH $1.54
- SYBX $1.36
- Resistance Level
- MGIH $2.87
- SYBX $1.47
- Average True Range (ATR)
- MGIH 0.43
- SYBX 0.08
- MACD
- MGIH 0.00
- SYBX 0.00
- Stochastic Oscillator
- MGIH 22.79
- SYBX 62.50
About MGIH Millennium Group International Holdings Limited
Millennium Group International Holdings Ltd is a paper-based packaging solutions supplier. It offers paper-based inner and outer packaging products which can be broadly categorized into packaging products, Packaging products supply chain management solutions and corrugated products.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.